Cytox welcomes enquiries from all organisations interested in our groundbreaking approach to identify an individual’s genetic risk component for developing Alzheimer's disease:
Our commercial ready testing services are available today in North America and Europe as prognostic tests for identifying those at highest risk for cognitive decline and developing Alzheimer’s disease by organisations such as pharmaceutical and biotechnology companies, CROs and grant funded academic researchers. These entities are seeking more accurate and affordable prognostic approaches for identifying those at highest risk for cognitive decline and developing Alzheimer’s disease
Collaborators who want to learn more about how Cytox can license and commercialise their algorithms
Laboratory Services who want to offer our approach in Asia or Africa
Ecosystem partners who have synergistic technologies that could be taken to market together.